Clinical trial · Interventional
Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients
Exploring an Alternative Pre-operative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sentinel lymph node biopsy (SLNB) is crucial in the management of malignant melanoma treatment and is currently performed by pre-operatively inject a colloid nanomaterial labeled with Technetium (99mTc) as radioactive tracer. Intra-operatively, Patent Blue (PB) will be injected to improve the visualization of the lymphatic tract. However, current pre-operative SLN mapping technique is associated with disadvantages as radiation exposure for both patients and health care staff and logistic challenges, because of time constraints due to short half-live time of 99mTc. Superparamagnetic iron oxide (SPIO) is a non-radioactive technique using a magnetic tracer (Magtrace® (Endomagnetics Ltd.)) to identify SLNs. Several studies showed that SPIO is non-inferior to dual tracing with 99mTc and PB in breast cancer patients. SPIO is expected to be non-inferior to dual tracing with 99mTc and PB in melanoma patients. However, further research is needed to demonstrate the use of SPIO in pre-operative MRI scanning. The primary objective of this study is to evaluate the feasibility and diagnostic accuracy of pre-operative MRI scanning using SPIO compared to lymphoscintigraphy (LS) and single-photon emission computed tomography/computed tomography (SPECT/CT) using 99mTc for identifying SLN status in melanoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Test: Sentinel node mapping using MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Melanoma patients
- description
- All patients will undergo lymphatic mapping with SPIO, 99mTc and PB.
- interventionNames
- Diagnostic Test: Diagnostic Test: Sentinel node mapping using MRI
Primary outcomes (1)
- measure
- The diagnostic accuracy of SPIO/MRI and LS+SPECT/CT and 99mTc to identify SLN
- timeFrame
- Before surgery (MRI scanning and scintigraphy)
- description
- The diagnostic accuracy of SPIO/MRI and LS+SPECT/CT and 99mTc to identify SLN will be expressed as sensitivity and specificity, and positive and negative predictive values, including their 95% exact binomial confidence intervals. MRI image analyses will be performed by two independent professionals.
Secondary outcomes (3)
- measure
- The diagnostic accuracy of SPIO/magnetometer and PB, 99mTc and Gamma probe
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥18 years of age at the time of consent; * Histological confirmed melanoma (patient must have primary cutaneous melanoma with Breslow thickness ≥ 0.8-2.0mm with or without ulceration or \<0.8mm with ulceration (pT1b - pT2b, AJCC 8th edition)); * Indication for wide local excision (margin 1 cm) and SLN procedure; * Patients should be willing and able to provide informed consent. Exclusion Criteria: * Intolerance/hypersensitivity to 99mTc-nanocolloid, PB, iron or dextran compounds; * Iron overload disease; * Pregnant or breast-feeding women; * Previous surrounded lymph node surgery; * Patients with head and neck melanomas; * Standard MRI exclusion criteria; * Implantable (electrical) devices (e.g. pacemaker, cochlear implants, neurostimulator); * Any other metal implants; * Claustrophobia; * MR-incompatible prosthetic heart valves; * Patients who are unable or refuse to provide informed consent.
References
Publications (0)
Data not yet available